Biotricity, Inc. (BTCY)
USD 0.5
(2.04%)
USD 0.5
(2.04%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 | -8.82 Million USD | 42.24% |
| 2023 | -15.4 Million USD | 12.81% |
| 2022 | -18.02 Million USD | -33.21% |
| 2021 | -13.35 Million USD | -22.95% |
| 2020 | -10.93 Million USD | -27.02% |
| 2019 | -8.59 Million USD | -11.24% |
| 2018 | - USD | -29.98% |
| 2017 | -5.94 Million USD | -15.83% |
| 2016 | -5.12 Million USD | -5625.58% |
| 2015 | - USD | 0.36% |
| 2014 | -89.92 Thousand USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 FY | - USD | 45.74% |
| 2024 Q1 | -2.29 Million USD | -3.03% |
| 2024 Q3 | -1.18 Million USD | 45.22% |
| 2024 Q4 | -2.94 Million USD | -130.02% |
| 2024 Q2 | -2.32 Million USD | -5.05% |
| 2023 Q3 | -4.36 Million USD | -7.39% |
| 2023 Q2 | -4.06 Million USD | 1.78% |
| 2023 FY | - USD | 12.81% |
| 2023 Q1 | -4.13 Million USD | 19.68% |
| 2023 Q4 | -2.22 Million USD | 49.0% |
| 2022 Q4 | -5.15 Million USD | -3.05% |
| 2022 Q3 | -4.99 Million USD | 16.48% |
| 2022 Q2 | -5.98 Million USD | -98.08% |
| 2022 Q1 | -3.02 Million USD | 24.77% |
| 2022 FY | - USD | -33.21% |
| 2021 Q1 | -3.57 Million USD | 20.06% |
| 2021 FY | - USD | -22.95% |
| 2021 Q2 | -2.84 Million USD | 20.25% |
| 2021 Q3 | -3.86 Million USD | -35.79% |
| 2021 Q4 | -4.01 Million USD | -3.82% |
| 2020 Q2 | -2 Million USD | 3.9% |
| 2020 Q3 | -2.34 Million USD | -16.85% |
| 2020 FY | - USD | -27.02% |
| 2020 Q1 | -2.08 Million USD | -14.65% |
| 2020 Q4 | -4.46 Million USD | -90.48% |
| 2019 Q1 | -2.42 Million USD | 13.29% |
| 2019 FY | - USD | -11.24% |
| 2019 Q3 | -2.17 Million USD | 0.21% |
| 2019 Q2 | -2.17 Million USD | 10.07% |
| 2019 Q4 | -1.82 Million USD | 16.1% |
| 2018 Q1 | -1.33 Million USD | 13.36% |
| 2018 Q2 | -1.45 Million USD | -8.6% |
| 2018 Q3 | -2.09 Million USD | -44.04% |
| 2018 Q4 | -2.79 Million USD | -33.21% |
| 2018 FY | - USD | -29.98% |
| 2017 Q1 | -800.8 Thousand USD | -38.88% |
| 2017 Q4 | -1.54 Million USD | 29.46% |
| 2017 FY | - USD | -15.83% |
| 2017 Q3 | -2.19 Million USD | -56.24% |
| 2017 Q2 | -1.4 Million USD | -75.21% |
| 2016 Q2 | -1.22 Million USD | -149.3% |
| 2016 FY | - USD | -5625.58% |
| 2016 Q4 | -576.62 Thousand USD | 59.86% |
| 2016 Q3 | -1.43 Million USD | -17.11% |
| 2016 Q1 | -492.01 Thousand USD | 0.0% |
| 2015 Q1 | -27.64 Thousand USD | 0.0% |
| 2015 Q2 | -20.58 Thousand USD | 25.52% |
| 2015 Q3 | -18.9 Thousand USD | 8.18% |
| 2015 FY | - USD | 0.36% |
| 2014 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Acutus Medical, Inc. | -13.48 Million USD | 34.542% |
| Cell MedX Corp. | - USD | Infinity% |
| Dynatronics Corporation | -976 Thousand USD | -804.528% |
| Nemaura Medical Inc. | -7.28 Million USD | -21.15% |
| PetVivo Holdings, Inc. | -10.49 Million USD | 15.877% |
| RetinalGenix Technologies Inc. | -2.08 Million USD | -323.023% |
| Sonendo, Inc. | -54.76 Million USD | 83.881% |
| Telesis Bio, Inc. | -40.49 Million USD | 78.198% |
| Talis Biomedical Corporation | -66.04 Million USD | 86.633% |
| Viveve Medical, Inc. | -20.61 Million USD | 57.18% |